Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet

2011 ◽  
Vol 42 (6) ◽  
pp. 1133-1137 ◽  
Author(s):  
Maureen C. Early ◽  
Craig A. Erickson ◽  
Logan K. Wink ◽  
Christopher J. McDougle ◽  
Eric L. Scott
2006 ◽  
Vol 36 (4) ◽  
pp. 471-474 ◽  
Author(s):  
Nahit Motavalli Mukaddes ◽  
Zerrin Topcu

1990 ◽  
Vol 149 (8) ◽  
pp. 567-569 ◽  
Author(s):  
J. D. Morrow ◽  
B. Y. Whitman ◽  
P. J. Accardo

1951 ◽  
Vol 21 (3) ◽  
pp. 559-570 ◽  
Author(s):  
George C. Darr ◽  
Frederic G. Worden

2016 ◽  
Vol 33 (S1) ◽  
pp. S631-S631
Author(s):  
M. García Moreno ◽  
A. De Cós Milas ◽  
L. Beatobe Carreño ◽  
B. Poza Cano

IntroductionAutistic disorder (AD) is a neuropsychiatric disorder that often presents significant disruptive symptoms such as irritability, aggression and self-injury in addition to impairment of social skills and communication. These symptoms interfere both individuals with AD and their families and social environment.ObjectiveShow paliperidone effect in behavioural symptoms in AD.MethodsLiterature review about behavioural symptoms in AD and paliperidone effect in its treatment, followed by a case report of clinical improvement after treatment with paliperidone in a patient with autism. Agitation subscale Aberrant Behavior Checklist (ABC-I) scores was compared prior and 4 weeks after paliperidone treatment, and clinical improvement was assessed with Clinical Global Impression-Improvement Scale (CGI-I).ResultsAlthough risperidone has been one of the most studied atypical antipsychotic to treat this symptoms, its use should be limited in order to avoid extrapyramidal and metabolic symptoms. Paliperidone – the major metabolite of risperidone – has shown effectiveness in the treatment of behavioral symptoms in patients with autism, even in subjects with a prior ineffective trial of risperidone. Our patient, 21-years-old male with AD and significant disruptive symptoms was treated with paliperidone 9 mg/day. We observed a 20-points reduction in ABC-I scores 4 weeks later, with most significant improvement in items like auto-agression, heteroaggressivity, irritability and slams. CGI-I scores showed a much better improvement, and no significant adverse effects appeared.ConclusionsPaliperidone is an effective and safe treatment in behavioral symptoms associated to AD, with reduction in ABC-I subscale scores. More studies are needed to confirm our data.Disclosure of interestThe authors have not supplied their declaration of competing interest.


2009 ◽  
Vol 2 (1) ◽  
pp. 27 ◽  
Author(s):  
David J Wu ◽  
Nicholas J Wang ◽  
Jennette Driscoll ◽  
Naghmeh Dorrani ◽  
Dahai Liu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document